Overview

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of homoharringtonine in treating patients who have chronic phase chronic myelogenous leukemia. Drugs used in chemotherapy, such as homoharringtonine, work in different ways to stop cancer cells from dividing so they stop growing or die
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Harringtonines
Homoharringtonine